KR20210141539A - Ctla-4 및 pd-1 차단제를 포함하는 항암 조합 요법 - Google Patents
Ctla-4 및 pd-1 차단제를 포함하는 항암 조합 요법 Download PDFInfo
- Publication number
- KR20210141539A KR20210141539A KR1020217032365A KR20217032365A KR20210141539A KR 20210141539 A KR20210141539 A KR 20210141539A KR 1020217032365 A KR1020217032365 A KR 1020217032365A KR 20217032365 A KR20217032365 A KR 20217032365A KR 20210141539 A KR20210141539 A KR 20210141539A
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- amino acid
- ctla
- domain
- cdrs
- Prior art date
Links
- 0 C*C(CC1)C(*C*CC(N(C)C)=C)CC1SC=* Chemical compound C*C(CC1)C(*C*CC(N(C)C)=C)CC1SC=* 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962817749P | 2019-03-13 | 2019-03-13 | |
US62/817,749 | 2019-03-13 | ||
PCT/US2020/021783 WO2020185722A2 (en) | 2019-03-13 | 2020-03-10 | Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20210141539A true KR20210141539A (ko) | 2021-11-23 |
Family
ID=72426465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020217032365A KR20210141539A (ko) | 2019-03-13 | 2020-03-10 | Ctla-4 및 pd-1 차단제를 포함하는 항암 조합 요법 |
Country Status (11)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230110141A (ko) | 2022-01-14 | 2023-07-21 | 영남대학교 산학협력단 | PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4139340A1 (en) | 2020-04-22 | 2023-03-01 | Merck Sharp & Dohme LLC | Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer |
EP4286520A1 (en) * | 2021-01-29 | 2023-12-06 | Minghui Pharmaceutical (Hangzhou) Limited | Antigen binding protein and use thereof |
WO2022218383A1 (zh) * | 2021-04-14 | 2022-10-20 | 康方药业有限公司 | 抗体在抗肿瘤治疗中的用途 |
CN117203235A (zh) * | 2021-04-21 | 2023-12-08 | 和铂医药(上海)有限责任公司 | 结合ctla-4的抗体及其用途 |
US11932693B2 (en) * | 2022-05-12 | 2024-03-19 | BioNTech SE | Monoclonal antibodies directed against programmed death-1 protein and their use in medicine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
MX2016014753A (es) * | 2014-05-15 | 2017-03-06 | Bristol Myers Squibb Co | Tratamiento de cancer de pulmon con el uso de una combinacion de un anticuerpo de muerte anti-programada 1 (anti-pd-1) y otro agente anti-cancerigeno. |
JP2020512354A (ja) * | 2017-03-31 | 2020-04-23 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd−1のアンタゴニストと抗ctla4抗体との組み合わせでがんを処置するための組成物および方法 |
-
2020
- 2020-03-10 JP JP2021553837A patent/JP2022525071A/ja active Pending
- 2020-03-10 MX MX2021010997A patent/MX2021010997A/es unknown
- 2020-03-10 CN CN202080020847.XA patent/CN113631189A/zh active Pending
- 2020-03-10 US US17/436,857 patent/US20220411507A1/en active Pending
- 2020-03-10 BR BR112021017892A patent/BR112021017892A8/pt unknown
- 2020-03-10 AU AU2020234785A patent/AU2020234785A1/en active Pending
- 2020-03-10 EP EP20770048.5A patent/EP3937979A4/en active Pending
- 2020-03-10 KR KR1020217032365A patent/KR20210141539A/ko unknown
- 2020-03-10 MA MA055316A patent/MA55316A/fr unknown
- 2020-03-10 CA CA3132198A patent/CA3132198A1/en active Pending
- 2020-03-10 WO PCT/US2020/021783 patent/WO2020185722A2/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230110141A (ko) | 2022-01-14 | 2023-07-21 | 영남대학교 산학협력단 | PD-L1 단백질에 특이적으로 결합하는 Fab 단편 및 이의 용도 |
Also Published As
Publication number | Publication date |
---|---|
WO2020185722A2 (en) | 2020-09-17 |
AU2020234785A1 (en) | 2021-08-19 |
EP3937979A2 (en) | 2022-01-19 |
WO2020185722A3 (en) | 2020-11-12 |
MX2021010997A (es) | 2021-10-01 |
CA3132198A1 (en) | 2020-09-17 |
BR112021017892A8 (pt) | 2023-01-31 |
CN113631189A (zh) | 2021-11-09 |
MA55316A (fr) | 2022-01-19 |
US20220411507A1 (en) | 2022-12-29 |
BR112021017892A2 (US07943777-20110517-C00090.png) | 2021-12-07 |
EP3937979A4 (en) | 2023-03-08 |
JP2022525071A (ja) | 2022-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220411507A1 (en) | Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents | |
EP3389699B1 (en) | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof | |
KR102355609B1 (ko) | 다중 암 항원에 특이적으로 결합하는 삼중-특이적 결합 분자 및 그것의 사용 방법 | |
JP2024054340A (ja) | 癌の治療に用いるための細胞傷害誘導治療剤 | |
CA3104098A1 (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
KR20220032642A (ko) | 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체 | |
KR20170089881A (ko) | Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법 | |
JP6175590B1 (ja) | 癌の治療に用いるための細胞傷害誘導治療剤 | |
AU2017201231B2 (en) | ANTI-H7CR Antibodies | |
CN116057070A (zh) | 抗cd40结合分子和包括其的双特异性抗体 | |
CN111094982A (zh) | 用于治疗和诊断癌症的tim-3拮抗剂 | |
TW201811826A (zh) | 抗icos抗體 | |
KR20160124912A (ko) | Cd40l에 대해 지시된 도메인 항체를 사용하여 이식 거부를 치료하는 방법 | |
Segués et al. | Opportunities and challenges of bi-specific antibodies | |
US20200190194A1 (en) | Combination therapy | |
US20240218067A1 (en) | Anti-siglec compositions and uses thereof | |
CA3216324A1 (en) | Anti-siglec compositions and uses thereof | |
Ryan | Improving Combination Cancer Immunotherapy with a Novel, Dual-Specific Immunotherapeutic Platform that Links T Cell Costimulatory Pathways | |
CN116888156A (zh) | 非阻断性人ccr8结合剂 |